Aclarion Inc. (NASDAQ: ACON, ACONW) announced a commercial agreement with Weill Cornell Medicine to provide its Nociscan technology for a spine research study. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center.

The study, led by Dr. Jaspal Ricky Singh, is titled "A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease" and operates under IRB Protocol No. 22-06024915. The research aims to investigate whether the dose and quantity of bone marrow aspirate stem cell concentrate used for treating osteoarthritis and degenerative disc disease affects patient-reported functional outcomes and pain.

A subset of spine patients selected through Dr. Singh's clinical evaluation will be eligible for Nociscan evaluation. Dr. Singh serves as Vice Chair and Director of Interventional Spine at Weill Cornell Medicine and as a Rehabilitation Medicine Specialist at Och Spine.

"Our pioneering research into discogenic low back pain and cBMA (concentrated bone marrow aspirate) is an ideal opportunity to utilize the insights provided by Nociscan," Singh said in the announcement.

Nociscan is described as a software-as-a-service platform that uses magnetic resonance spectroscopy data to help physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology processes MRS data through cloud-based algorithms to quantify chemical biomarkers associated with disc pain.

The company states that approximately 266 million people worldwide suffer from degenerative spine disease and low back pain, according to information provided in the announcement.